Based on our success on blocking OSMR signaling using monoclonal antibody abrogated STAT3 signaling repressed cancer stemness, 3-dimensional (3-D) spheroid forming ability, and ovarian cancer growth and progression11, we characterized the potential of testing the effect of anti-OSMR antibodies to treat cisplatin-resistant ovarian cancer cells. The gene discussed is OSMR; the disease is ovarian carcinoma.